drugset / Trial / NCT01480739

AZD5069 Neutrophil Function Study

NCT01480739

Phase 1 Completed 30 enrolled AstraZeneca
RandomizedCrossoverDouble-blindBasic science

Summary

Study in healthy volunteer to see effect of AZD5069 and placebo on neutrophil number and function (phagocytosis and oxidative burst) in the circulation, following a burst of strenuous exercise and following subcutaneous injection of granulocyte-colony stimulating factor (G-CSF)

Timeline

Start
2011-12
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5069 Small molecule 50 mg Oral

Indications

No indication recorded.